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Dissemination of carcinoma cells requires the pericellular degra-
dation of the extracellular matrix, which is mediated by membrane
type 1-matrix metalloproteinase (MT1-MMP). In this article, we
report a co–up-regulation and colocalization of MT1-MMP and
atypical protein kinase C iota (aPKCι) in hormone receptor-nega-
tive breast tumors in association with a higher risk of metastasis.
Silencing of aPKC in invasive breast-tumor cell lines impaired the
delivery of MT1-MMP from late endocytic storage compartments
to the surface and inhibited matrix degradation and invasion. We
provide evidence that aPKCι, in association with MT1-MMP–con-
taining endosomes, phosphorylates cortactin, which is present in
F-actin–rich puncta on MT1-MMP–positive endosomes and regu-
lates cortactin association with the membrane scission protein
dynamin-2. Thus, cell line-based observations and clinical data re-
veal the concerted activity of aPKC, cortactin, and dynamin-2,
which control the trafficking of MT1-MMP from late endosome
to the plasma membrane and play an important role in the inva-
sive potential of breast-cancer cells.
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Metastasis—the process by which cells from a primary tumorinvade local tissues and disseminate to distant sites—
marks the transition from a benign tumor to a lethal, malignant
cancer. One intrinsic property of metastatic tumor cells that
allows them to breach tissue barriers is their ability to degrade
the proteins of the extracellular matrix (ECM). This remodeling
of the ECM by cancer cells depends on matrix-degrading pro-
teases, including matrix metalloproteinases (MMPs) (1, 2). Al-
though secreted MMPs have been implicated in cancer for several
decades, it is more recently that a subgroup of membrane-
anchored MMPs, including membrane type 1 (MT1)-MMP, have
been recognized as important proteases involved in dissemination
of tumor cells and cancer progression (3–7).
Membrane type 1-matrix metalloproteinase (MT1-MMP) is
up-regulated in human cancers, including breast cancers, and it is
enriched at the front of invasive lesions (8, 9). In tumor-derived
cells cultured on a flat ECM substratum, such as gelatin or type I
collagen, MT1-MMP accumulates in specialized matrix-degrad-
ing plasma-membrane domains called invadopodia (10). The
current view is that interaction of matrix receptors on the tumor-
cell surface with components of the ECM leads to assembly of
nascent invadopodia containing F-actin and cortactin, which
mature into matrix-degrading invadopodia when they accumu-
late MT1-MMP (11).
Little is known about how invadopodia form in metastatic cells
and how they are endowed with proteolytic activity. In MDA-
MB-231 human breast adenocarcinoma cells, newly synthesized
MT1-MMP passes through the secretory pathway to reach the
plasma membrane where it is then endocytosed (12). The ma-
jority of internalized MT1-MMP is located in a late endocytic
compartment from where a fraction recycles to plasma-mem-
brane invadopodia (13). Various studies, including our own, have
identified several components of the exocytic machinery that are
required for delivery of MT1-MMP to invadopodia, including
cortactin (a regulator of actin dynamics), the exocyst complex
(required for docking of transport vesicles), and vesicle-associ-
ated membrane protein 7 (VAMP7) (a late endosome v-SNARE
protein involved in vesicle fusion) (10, 13–16). Although these
findings provide important insights into how MT1-MMP is de-
livered to the invadopodial plasma membrane, the mechanisms
underlying the formation of MT1-MMP transport intermediates
from late endocytic compartments remain largely unexplored.
Atypical protein kinase C (aPKC) comprises a branch of the
serine/threonine PKC superfamily consisting of two isoforms,
aPKCς and aPKCι, that are distinct from the typical, diac-
ylglycerol-regulated isoforms (17). aPKCζ/ι are activated mainly
by components of the PAR complex, Cdc42 and Par-3, and play
a critical role in the formation of epithelial cell–cell junctions
and the development of apico-basal polarity in mammalian
epithelial cells (18). Previously, we reported the role of an
aPKCζ/ι–exocyst complex in signaling at the leading edge of
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migrating cells, so controlling paxillin phosphorylation and
regulating focal adhesion dynamics (19). In addition, several
lines of evidence implicate aPKCζ/ι in cancer: aPKCς is re-
quired for epidermal growth factor-induced chemotaxis of
human breast-cancer cells (20), and aPKCζ/ι promotes matrix
degradation by Src-transformed mouse NIH 3T3 fibroblasts
(21). Moreover, aPKCι expression is up-regulated in various
cancers, including breast cancer, and correlates with poor
prognosis (22, 23). The ability of aPKCζ/ι to control both cell
polarity and the migration of cells makes it a prime candidate
for a role in tumor progression and metastasis although the
specific functions of aPKCζ/ι in metastatic cells are currently
only poorly understood.
Here, we report an up-regulation and relocalization of MT1-
MMP and aPKCι in breast-tumor samples associated with a high
risk of metastasis. We found that silencing of aPKCζ/ι in human
breast adenocarcinoma cell lines impairs ECM degradation and
invasion of the cells into different reconstituted 3D matrix
environments. These functional effects of aPKCζ/ι silencing
correlate with defects in cortactin phosphorylation and distri-
bution and dynamin-2 (dyn-2) recruitment and function on MT1-
MMP–containing endosomes, resulting in impaired delivery of
MT1-MMP to the invadopodial plasma membrane. This study thus
identifies a previous unidentified coordinated function for aPKCζ/ι,
cortactin, and dyn-2 in the control of MT1-MMP trafficking from
late endosomes to the plasma membrane during breast-tumor
cell invasion, providing a rationale for the design of therapeutic
interventions.
Results
Co–Up-Regulation of MT1-MMP and aPKCι mRNAs Is Associated with
Adverse Clinical Outcomes in Breast Cancer. In previous studies,
we implicated the exocyst complex in MT1-MMP trafficking
to invadopodia in MDA-MB-231 breast-tumor cells (15) and
identified a coordinated function of the exocyst complex and
aPKCζ/ι in migrating cells (19). MT1-MMP and aPKCι are
overexpressed in various cancers, including breast cancers, and
up-regulation is associated with poor prognosis (8, 9, 22, 24).
These data suggested the possible interplay between MT1-MMP
and aPKCζ/ι in the invasive program of breast-tumor cells. Ex-
pression of MT1-MMP and 11 aPKCζ/ι family members was
investigated by qRT-PCR analysis in breast-tumor samples from
458 patients with unilateral invasive breast tumors and known
long-term outcome (Table S1). MT1-MMP expression corre-
lated most with aPKCι mRNA (r = +0.556, P < 10−7) (Table 1).
We looked for correlations between aPKCι and MT1-MMP
mRNA status and standard clinicopathological and biological
factors in this cohort. About one third of breast tumors tested
(153/458) showed aPKCι mRNA overexpression (a greater than
threefold increase compared with normal tissues), and 23.3%
(107/458) showed MT1-MMP mRNA overexpression (Table S1).
In the tumor group that overexpressed both aPKCι and MT1-
MMP, we saw a statistically significant association with histo-
pathological grade III (P = 0.0041), estrogen receptor (ER)-
negative (P = 0.0014), and progesterone receptor (PR)-negative
(P = 0.001) status, as well as with the molecular subtype (P =
0.003) (Table S1). Of note, 24.6% (17/69) of triple-negative
breast cancers (ER− PR− HER2−), a type of aggressive and
highly proliferative tumors, overexpressed MT1-MMP and
aPKCι vs. 12.8% (50/389) for the other subtypes (P = 0.011).
Furthermore, by combining aPKCι and MT1-MMP mRNA ex-
pression status, we identified four distinct prognostic groups with
significantly different metastasis-free survival (MFS) curves (P =
0.008) (Fig. 1A). The patients with the poorest prognosis had
both aPKCι and MT1-MMP mRNA overexpression whereas
those with the best prognosis had normal aPKCι and MT1-MMP
mRNA levels.
MT1-MMP and aPKCι Colocalize in Cytoplasmic Granules and at Cell–
Cell Contacts in Hormone Receptor-Negative Breast-Carcinoma Cells.
To investigate changes in protein levels and localization of MT1-
MMP and aPKCι during breast-tumor progression, a human
tissue microarray (TMA) of 68 breast tumors representative of
the four main molecular subtypes (Experimental Procedures) was
analyzed by immunohistocytochemistry (IHC), on consecutive
sections (25) (Dataset S1 and Fig. 1 B and C). Compared with
epithelial cells in surrounding nonneoplastic tissues, aPKCι was
overexpressed in cancer cells in all subtypes whereas expression
of MT1-MMP was significantly up-regulated in hormone receptor-
negative tumors (ER− PR−HER2+ and ER− PR−HER2−) (Dataset
S1, Fig. S1 A and B, and Fig. 1D). These data demonstrate a positive
correlation between aPKCι and MT1-MMP expression in hormone
receptor-negative subtypes of breast carcinomas at both the mRNA
and protein levels.
aPKCι staining was restricted to the apical surface of normal
breast epithelial cells lining the lumen of the duct whereas, in
tumor cells, overexpressed aPKCι lost its apical localization (Fig.
1B and Fig. S1C) and showed a predominant unpolarized dis-
tribution at cell–cell contacts and cytoplasmic granules in the
majority of the tumors (Fig. 1B and Fig. S1 D and E). There was
little or no aPKCι staining in the stroma. MT1-MMP was lat-
erally localized in luminal epithelial cells in normal tissues and
also expressed in myoepithelial cells (Fig. 1C and Fig. S1C).
MT1-MMP distribution was predominantly unpolarized in can-
cer cells in overexpressing tumors (Fig. 1C and Fig. S1C), with
both a strong cell–cell contact association and a granular cyto-
plasmic distribution (Fig. 1C and Fig. S1 D and E). Thus, in
contrast to their distinct localization at separate plasma-mem-
brane domains of normal luminal breast epithelial cells, aPKCι
and MT1-MMP significantly codistributed at cell–cell contacts
and cytoplasmic granules, including in hormone receptor-nega-
tive tumors. These findings correlating up-regulation of aPKCι
and MT1-MMP during breast-tumor progression indicate a poor
prognosis for these combined markers.
aPKCζ/ι Is Required for MT1-MMP–Dependent Matrix Degradation
and Breast-Tumor Cell Invasion. The functional interplay between
MT1-MMP and aPKCι in tumor-cell invasion was investigated in
MDA-MB-231 and BT-549 cells, two cell lines that can be
classified as triple-negative breast cancer (26). Silencing of MT1-
MMP expression strongly diminished invadopodial degradation
of gelatin (Fig. 2 A and B) (10, 15). We investigated whether
Table 1. Correlation using the Spearman’s rank correlation test
between 11 genes of the PKC family and MT1-MMP mRNA
expression in human breast cancer
Gene (protein)
Spearman correlation
coefficient P*
PRKCA (PKCα) 0.233 0.0000021
PRKCE (PKCe) 0.045 0.34 (NS)
PRKCH (PKCη) 0.157 0.0009
PKN2 (PKN2) 0.061 0.19 (NS)
PRKCZ (PKCζ) 0.10 0.82 (NS)
PRKCD (PKCδ) 0.016 0.74 (NS)
PRKCQ (PKCθ) −0.054 0.24 (NS)
PRKCI (PKCι) 0.556 < 0.0000001
PRKCB (PKCβ) 0.389 < 0.0000001
PKN1 (PKN1) 0.199 0.000038
Expression of genes encoding PKCs and MT1-MMP was analyzed by re-
verse transcriptase-quantitative polymerase chain reaction (RT-qPCR) of 458
mRNA tumor samples. Very low levels of mRNA encoding PKCγ were detect-
able but not reliably quantifiable by RT-qPCR assays using the fluorescence
SYBR green methodology (cycle threshold > 35). NS, not significant.
*P value of Spearman rank correlation test. In bold type, significant P values.
Rossé et al. PNAS | Published online April 21, 2014 | E1873
CE
LL
BI
O
LO
G
Y
PN
A
S
PL
U
S
aPKCζ/ι played a role in MT1-MMP–dependent matrix pro-
teolysis by silencing both aPKCζ and aPKCι in these cell lines
using two independent pairs of siRNAs (Fig. 2 A and B, Insets,
immunoblots and Fig. S2 A and B) and then quantifying matrix
degradation. Compared with cells treated with an irrelevant
siRNA (luciferase, siLuc), these cells showed a 60–70% re-
duction of their degradative capacity (Fig. 2 A and B and Fig. S2
C and D). This inhibition of matrix degradation in the absence of
aPKCζ/ι was not due to alteration of MT1-MMP levels in the
cells (Fig. 2 A and B, Insets, immunoblots and Fig. S2 A and B).
Furthermore, overexpression of MT1-MMP overcompensated
the adverse effect of aPKCζ/ι silencing on gelatin degradation
(Fig. 2C, compare red bars and black bars). These data indicate
that aPKCζ/ι is required for matrix proteolysis by breast-tumor
cells through the control of MT1-MMP function.
We further assessed the effect of aPKCζ/ι silencing on MDA-
MB-231 cell invasion across a thick layer of Matrigel and on
invasive migration through fibrous type I collagen because MT1-
MMP is required for invasion in these environments (13, 27).
Double silencing of aPKCζ and aPKCι impaired invasion in
Matrigel to a similar extent to silencing of MT1-MMP itself (Fig.
2D). Similarly, silencing of both aPKCζ and -ι inhibited the
dissemination of MDA-MB-231 cells from multicellular sphe-
roids into the surrounding 3D gel of type I collagen (Fig. 2 E and
Fig. 1. Co–up-regulation and colocalization of MT1-MMP and aPKCι in
hormone receptor-negative breast tumors correlate with poor prognosis. (A)
Metastasis-free survival (MFS) curves for breast-tumor patients with normal
(Norm) or overexpressed (Overexp, >3) aPKCι and MT1-MMP mRNA levels
(Spearman rank). (B and C) aPKCι (B) and MT1-MMP (C) immunohisto-
chemistry staining on consecutive sections of human breast tumor TMAs
showing adjacent nonneoplastic tissue and representative ER− PR− HER2−/
triple-negative tumors. Note that adjacent nonneoplastic tissue shown in
Top panels correspond to tumor sample shown in Middle panels. Right
panels show higher magnification. [Scale bars: 20 μm (Left) and 5 μm
(Right).] (D) Intensity scoring of aPKCι (black bars) and MT1-MMP (red bars)
immunohistochemistry staining (on a 0-to-3 scale as documented in Fig. S1 A
and B) of a tissue microarray of human breast tumors representative of the
different molecular subtypes and adjacent nonneoplastic areas (Normal
breast tissue). Breast molecular subtypes were defined as follows: luminal A+
B according to ref. 52 [luminal A, estrogen receptor (ER) ≥ 10%, pro-
gesterone receptor (PR) ≥ 20%, Ki67 < 14%; luminal B, ER ≥ 10%, PR < 20%,
Ki67 ≥ 14%]; ER− PR− HER2+, ER < 10%, PR < 10%, HER2 2+ amplified or 3+
according to ref. 53; ER− PR− HER2− (triple-negative), ER < 10%, PR < 10%,
HER2 0/1+ or 2+ nonamplified according to ASCO guidelines (53). n, the
number of tumors analyzed. *P < 0.05; ***P < 0.001; ns, non significant
compared with normal adjacent tissues (χ2 test). Note that intensity scores of
MT1-MMP expression in luminal A+B tumors are inferior to normal tissues.
Fig. 2. Atypical PKCζ/ι regulate MT1-MMP–dependent matrix degradation
and invasion. (A and B) Quantification of FITC–gelatin degradation by MDA-
MB-231 (A) and BT-549 cells (B) treated with indicated siRNAs. Values are
means ± SEM of the normalized degradation area from at least three in-
dependent experiments. (Insets) Immunoblotting with antibodies against
aPKCζ/ι and MT1-MMP of cells treated with the indicated siRNAs. Immuno-
blotting with antibodies against GAPDH served as a control for loading. (C)
Quantification of FITC–gelatin degradation byMDA-MB-231 stably expressing
MT1-MMP–mCherry treated with the indicated siRNAs (red bars) compared
with untransfectedMDA-MB-231 cells (black bars). Note the logarithmic scale.
(D) MDA-MB-231 cells treated with indicated siRNAs were tested for their
ability to invade through Matrigel. Values are means ± SEM normalized to
the mean for siLuc-treated cells. *P < 0.05; **P < 0.01. (E) Multicellular
spheroids of MDA-MB-231 cells treated with siRNAs against luciferase or
aPKCζ/ι (siaPKCζ/ι-2) were embedded in 3D acid-extracted type I collagen (T0)
and further incubated for 2 d (T2). Images show phalloidin-labeled spheroids
collected at T2 (Insets correspond to spheroids at T0). (Scale bars: 200 μm.) (F)
Data are mean invasion area in type I collagen at T2 normalized to the mean
invasion area at T0 ± SEM (n = 3 independent experiments; 15–20 spheroids
were analyzed for each cell population). ***P < 0.001.
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F). These data indicate that aPKCζ/ι is required for MT1-MMP–
dependent invasion of MDA-MB-231 cells in two different
reconstituted matrices that mimic the 3D environment of cancer
cells in vivo.
Atypical PKCζ/ι Control MT1-MMP–Containing Endosome Distribution
and MT1-MMP Exocytosis. Immunoelectron microscopy of MDA-
MB-231 cells stably expressing MT1-MMP–mCherry revealed as-
sociation of MT1-MMP with the limiting membrane and internal
luminal vesicles of vesicular compartments, with morphology typ-
ical of multivesicular bodies (Fig. 3A). These observations are
consistent with the predominant association of MT1-MMP with
VAMP7- and Rab7-positive late endocytic compartments in
MDA-MB-231 cells (13, 16). Imaging of live cells expressing
GFP–aPKCι revealed an association of this protein with ∼32%
of MT1-MMP–mCherry–positive vesicles (Fig. 3B and Fig. S2E),
reminiscent of the colocalization of aPKCι and MT1-MMP on
cytoplasmic granular compartments in hormone receptor-nega-
tive breast carcinoma (Fig. 1C and Fig. S1E).
We investigated whether aPKCζ/ι may be required for MT1-
MMP trafficking to the plasma membrane. Expression of a con-
stitutively active allele of aPKCι resulted in an ∼1.5-fold increase
of the density of MT1-MMP–containing vesicles in the vicinity of
the plasma membrane visualized by total interference reflection
fluorescence microscopy (TIRFM) (Fig. 3 C and D and Fig.
S2F). On the contrary, aPKCζ/ι depletion induced a twofold
reduction in MT1-MMP–positive endosomes at the plasma
membrane (Fig. 3E and Fig. S2G). The contribution of aPKCζ/ι
to MT1-MMP delivery to the invadopodial plasma membrane
was assessed by quantifying surface accumulation of MT1-
MMP–pHluorin (28); fluorescence of this construct is eclipsed in
the acidic environment of the late endosome and rises immedi-
ately upon exocytosis and exposure to the extracellular pH (29).
As expected, MT1-MMP–pHluorin accumulated at the level of
cortactin-positive invadopodia on the ventral cell surface (Fig.
3F). Knockdown of aPKCζ/ι led to a 40–60% reduction of
plasma-membrane accumulation of MT1-MMP–pHluorin, simi-
lar to the effect of cortactin siRNA, which is required for MT1-
MMP delivery to invadopodia (10, 14) (Fig. 3G). All together,
these data reveal that aPKCζ/ι controls the polarization of MT1-
MMP–positive endosomes to the cell surface and MT1-MMP
exocytosis and regulates pericellular matrix remodeling.
Dynamin-2 Associates with Cortactin on MT1-MMP–Positive Endosomes
in an aPKCζ/ι-Dependent Manner and Is Required for MT1-MMP
Trafficking and Matrix Degradation. Analysis of the subcellular
distribution of cortactin by indirect immunofluorescence in
MDA-MB-231 cells revealed that, in addition to its invadopodial
location (Fig. 3F and Fig. S2 C and D) (10, 14), cortactin also
accumulated in the central region of the cell and was dynamically
associated with MT1-MMP–containing endosomes (more than
95% of MT1-MMP–positive endosomes harbored at least one
cortactin-rich puncta) (Fig. 4A and Movie S1). In addition, F-
actin and the p34-Arc subunit of Arp2/3 complex, which are
components of the cytoskeleton and partner proteins of cortactin,
colocalized with cortactin patches on MT1-MMP–containing
endosomes in MDA-MB-231 and BT-549 cells (Fig. S3 A–C).
High-resolution structured illumination microscopy revealed the
presence of distinct submicrometer-sized cortactin domains
associated with MT1-MMP–positive endosomes (Fig. S3D).
Knockdown of aPKCζ/ι induced coalescence of the cortactin
domains on MT1-MMP–containing endosomes (Fig. 4A and
Fig. S3D) and a dramatic ∼80% increase of cortactin on MT1-
MMP–positive endosomes (Fig. 4B). These data demonstrate
that cortactin associates with F-actin assemblies on MT1-
MMP–positive endosomes in an aPKCζ/ι-regulated manner.
The endosomal actin and cortactin cytoskeleton is known to
regulate the formation and fission of tubulovesicular transport
carriers involved in the recycling of surface proteins within the
endocytic pathway (30, 31). We looked at the dynamic distribu-
tion of the late endocytic marker GFP–Rab7, which is associated
with MT1-MMP–positive endosomes and colocalizes with
endosomal cortactin (Fig. S3E) (32). By live-cell imaging, we
observed the formation of GFP–Rab7-positive tubules emanating
from MT1-MMP–containing endosomes and the fission of these
tubules (Fig. S3F, Upper). Silencing of aPKCζ/ι, by contrast,
was accompanied by more persistent Rab7– and MT1-MMP–
containing tubular extensions (Fig. S3 E, Right and F, Lower),
suggesting that aPKCζ/ι controls MT1-MMP–containing late
endosome membrane remodeling.
Fig. 3. aPKCζ/ι regulate MT1-MMP trafficking to plasma membrane
invadopodia. (A) Ultrathin cryosection of MDA-MB-231 cells expressing
MT1-MMP–mCherry labeled with MT1-MMP antibody followed by pro-
tein A-gold. Red arrows, MT1-MMP in the limiting membrane; black
arrows, MT1-MMP associated with intraluminal vesicles of late endo-
somes/multivesicular bodies (LE/MVB). (Scale bars: 500 nm.) (B) Confocal
spinning-disk microscopy image of an MDA-MB-231 cell expressing GFP–
aPKCι and MT1-MMP–mCherry. [Scale bars: 5 μm (Left) and 1 μm (Right,
boxed region at higher magnification). (C ) MDA-MB-231 expressing MT1-
MMP–mCherry alone or together with constitutively active aPKCι were
imaged by TIRFM. (Insets) Corresponding wide-field images showing
equal MT1-MMP expression. (Scale bar: 5 μm.) (D and E ) Integrated in-
tensity of MT1-MMP–mCherry signal per unit membrane area measured
from TIRFM images. Values represent mean percentage of membrane
MT1-MMP normalized to cells expressing only MT1-MMP–mCherry (D) or
siLuc-treated cells (E ) ± SEM. *P < 0.05; ***P < 0.001. (F ) MDA-MB-231
cells expressing MT1-MMP–pHluorin and DsRed-cortactin plated on cross-
linked gelatin and analyzed by dual color TIRFM. (Insets) Split signals
from the boxed region. (Scale bar: 5 μm.) (G) Plots show the percentage
of cells with MT1-MMP–pHluorin–positive invadopodia. Efficiency of
cortactin knockdown is shown in Fig. 4G. Values are means ± SEM from
three independent experiments scoring a total of 150–200 cells for each
cell population. **P < 0.01; ***P < 0.001 (compared with cells treated
with siLuc siRNA).
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Cortactin regulates membrane dynamics through its in-
teraction with dyn-2, which is involved in membrane scission
and is required for the formation and function of invadopodia
(33, 34). We therefore analyzed the location of endogenous
dyn-2 and cortactin by immunolabeling MDA-MB-231 cells
stably expressing MT1-MMP–mCherry. This immunolabeling
revealed a close apposition of dyn-2 patches with cortactin
puncta on ∼90% of MT1-MMP–positive endosomes (Fig. 4C,
internal plane). Note that, as expected, dyn-2 associated with
clathrin-coated pits on the plasma membrane with partial
colocalization with cortactin (Fig. 4C, ventral plane). When
coexpressed with DsRed–cortactin, GFP–dyn-2 colocalized
with cortactin domains on vesicular structures in the central-
cell region (Fig. 4D and Movie S2). In addition, deletion of the
proline-rich domain (ΔPRD) of dyn-2, which mediates its in-
teraction with the SH3 domain of cortactin (33), abolished
dyn-2 association with MT1-MMP–containing vesicles (Fig.
S4A). Reciprocally, expression of a DsRed–cortactin protein
lacking the SH3 domain (cortactinΔSH3) resulted in a diffuse
cytosolic distribution of GFP–dyn-2 (Fig. S4B and quantifi-
cation in Fig. 5C). These data demonstrate that dyn-2 coloc-
alizes with cortactin on MT1-MMP–containing endosomes
and indicate a cortactin-dependent, possibly transient associ-
ation of dyn-2 with these endosomes.
The observation that loss of aPKCζ/ι activity triggered accu-
mulation of Rab7– and MT1-MMP–positive membrane tubules
(Fig. S3 E and F) prompted us to investigate whether accumu-
lation of cortactin on MT1-MMP–containing endosomes in
aPKCζ/ι-depleted cells affected dyn-2 recruitment and conse-
quently tubule fission. To do so, we silenced aPKCζ/ι in MDA-
MB-231 cells and observed a reduction of GFP–Dyn-2 re-
cruitment associated with DsRed–cortactin patches along with
increased endosomal cortactin accumulation (Fig. 4E and
Fig. S4C, internal plane). Analysis of the intensity ratio of the
fluorescence signals from GFP–dyn-2 and DsRed–cortactin in
endosomal patches showed that the intensity ratio in aPKCζ/ι-
depleted cells was reduced by 60% compared with the control—
siLuc-treated—cells (Fig. 4F). In contrast, aPKCζ/ι knockdown
did not affect the association of Dyn-2 with clathrin-coated pits at
the plasma membrane (Fig. S4C, ventral plane). Thus, we con-
clude that accumulation of cortactin in the absence of aPKCζ/ι
function interferes specifically with Dyn-2 recruitment on MT1-
MMP–containing late endosomes. In addition, in agreement with
previous findings (34), silencing of dyn-2 in MDA-MB-231 cells
correlated with a substantial loss of their ability to degrade the
matrix similar to the effect of cortactin knockdown (Fig. 4G).
Accumulation of MT1-MMP–positive vesicles and tubules con-
nected to and extending from MT1-MMP–containing endosomes
was visible in Dyn-2–depleted cells (Fig. S4 D and E and Movie
S3). Collectively, these data indicate that dyn-2 acts downstream
of cortactin and that aPKCζ/ι is required for the formation and
function of cortactin–dyn-2 assemblies on multivesicular bodies/
late endosomes, suggesting a mechanism involved in the forma-
tion and fission of tubulovesicular carriers from these endosomes.
aPKCζ/ι-Dependent Phosphorylation of Cortactin Controls Its
Association with dyn-2. We then addressed how aPKCζ/ι con-
trols cortactin and dyn-2 association on MT1-MMP–containing
endosomes. We tested whether cortactin was a direct substrate
for aPKCζ/ι by incubating purified GST-tagged human cortactin
in the presence of recombinant human aPKCι. Phosphorylation
was detected with antibodies raised against cortactin phospho-
Ser298, which was recently identified as a phosphorylation site
for aPKCζ/ι-related PKD (35, 36). In higher metazoans, mRNA
splicing generates cortactin variants with four, five, or six con-
served tandem actin-binding repeats in which repeats 5 and 6
are the most conserved (37). The cortactin variant used for this
study contains five tandem repeats; Ser261 in repeat 5 is highly
conserved and equivalent to Ser298 in repeat 6. Recombinant
aPKCι induced phosphorylation of recombinant human cor-
tactin (Fig. 5A). In addition, coexpression of the five repeat-
containing cortactin variant (33) with aPKCι in MDA-MB-231
cells similarly resulted in phosphorylation of cortactin (Fig. 5B).
Thus, our data suggest that Ser261 is directly phosphorylated
by aPKCι.
Next, we investigated the consequences of substitution of
serine 261 to alanine (nonphosphorylable mutation) or to as-
partate (phosphomimetic mutation) on gelatin degradation.
Fig. 4. aPKCζ/ι regulates cortactin and dynamin-2 recruitment on MT1-
MMP–positive endosomes. (A) MDA-MB-231 cells stably expressing MT1-
MMP–mCherry (red) were treated with indicated siRNAs, plated on gelatin,
and immunolabeled with an antibody against cortactin (in green). [Scale
bars: 5 μm (entire cell) and 1 μm (boxed region at higher magnification,
Right panel of each row).] (B) Quantification of cortactin on MT1-MMP–
mCherry–containing vesicles in deconvoluted image stacks of MDA-MD-231
cells as in A. The x axis indicates mean cortactin intensity associated with
MT1-MMP–mCherry–containing endosomes normalized to the value in
control siLuc-treated cells (in percentage) ± SEM (from 50 cells from each cell
population). ***P < 0.001. (C) MDA-MB-231 cells expressing MT1-MMP–
mCherry (red) were immunolabeled for cortactin (blue) and dyn-2 (green).
(Left) The distribution of dyn-2 on the ventral plane of the cell in clathrin-
coated pits with partial association with cortactin. (Center) Documents dyn-
2’s association with cortactin-positive puncta on MT1-MMP–mCherry vesicles
(arrows). (Right) A higher magnification of the boxed region. [Scale bars: 5
μm (Left and Center) and 1 μm (Right)]. (D) Confocal spinning-disk micros-
copy image of MDA-MB-231 cells expressing GFP–dyn2 and DsRed–cortactin
(Movie S2). [Scale bars: 5 μm (Upper) and 1 μm (Lower). (E) Dual-color con-
focal spinning-disk microscopy of MDA-MB-231 cells expressing DsRed–cor-
tactin and GFP–dyn-2 and treated with indicated siRNAs. (Scale bars: 5 μm.)
(F) The ratio of signal intensities from GFP–dyn-2 and DsRed–cortactin was
measured for 200 and 290 endosomal cortactin patches in cells treated with
siRNAs against luciferase or aPKC, respectively. ***P < 0.001. (G) Quantifi-
cation of gelatin degradation by MDA-MB-231 cells treated with indicated
siRNAs. Values are means ± SEM of the normalized degradation area from
three independent experiments. (Inset) Immunoblotting with indicated
antibodies using tubulin as a control for loading.
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Overexpression of cortactin S261A in BT-549 cells led to an ∼50%
reduction in matrix degradation whereas cortactin S261D had the
opposite stimulatory effect (Fig. S4F). In addition, similar to the
loss of aPKCζ/ι (Fig. 4 E and F), expression of cortactin-S261A
caused drastic and specific depletion of dyn-2 from endosomal
patches (Fig. 5C and Fig. S4G). By contrast, mutation of the ex-
tracellular signal-regulated serine/threonine kinase (ERK1/2)
phosphorylation sites S405 and S418 of cortactin into alanine did
not affect dyn-2 association with endosomes (Fig. 5C). Over-
expression of the phosphomimetic cortactin S261D variant did
not affect significantly dyn-2 recruitment on MT1-MMP–con-
taining endosomes (Fig. 5C), suggesting that aPKCζ/ι-mediated
phosphorylation of cortactin may also affect the dynamics of
dyn-2 association to MT1-MMP–positive late endosomes. Fi-
nally, we observed that, in breast tumors, increased total phos-
phorylated aPKCι correlated with high cortactin expression and
phosphorylation at the aPKCι-specific site in the actin-binding
repeats (Fig. 5D). Together, our data indicate that aPKCι-mediated
phosphorylation of cortactin regulates endosomal accumulation of
cortactin and its association with dyn-2 to control MT1-MMP–
positive endosome dynamics during the invasive program of breast-
tumor cells.
Discussion
In this study, we report an unprecedented function for aPKCζ/ι
in the invasion of breast-tumor cells. Our data show that aPKCζ/ι
silencing in two breast-adenocarcinoma cell lines representative
of triple-negative breast cancers inhibits MT1-MMP–dependent
matrix degradation and tumor-cell invasion, while having no
effect on MT1-MMP expression. Instead, aPKCζ/ι controls the
trafficking and plasma-membrane targeting of MT1-MMP to
invadopodia. In MDA-MB-231 and BT-549 cells, aPKCζ/ι
associates partially with cortactin and its binding partners,
F-actin and dyn-2, in patches on late endosomes that contain an
intracellular reservoir of the transmembrane metalloproteinase
MT1-MMP. aPKCζ/ι phosphorylates cortactin directly, and
depletion of the kinase interferes with cortactin-dependent
recruitment of the membrane scission protein dyn-2, correlat-
ing with tubulation of endosomal membranes and impaired
trafficking and exocytosis of MT1-MMP to the cell surface.
Thus, we conclude that aPKCζ/ι promotes the formation of
transport vesicles carrying MT1-MMP (and possibly other
proteins involved in invasion such as integrins) (38) from its
intracellular reservoir in late endosomes to the cell surface,
where it contributes to preparing the extracellular matrix for
the invasion of the tumor cells. Consistent with this mechanism,
our analysis of breast-tumor biopsies shows overexpression of
both aPKCι and MT1-MMP in the most aggressive hormone
receptor-negative HER2+ and triple-negative subtypes. These
proteins are found at cell–cell contacts and in intracellular
vesicles in carcinoma cells, contrasting with their distinct loca-
tions on the apical and lateral plasma membranes, respectively,
in healthy breast epithelial cells. The positive correlation be-
tween MT1-MMP and aPKCι mRNA expression in clinical
samples was associated with poor prognosis, underscoring the
functional importance of the kinase in progress of the disease.
The direct phosphorylation of cortactin residue S261 by aPKCι,
as well as the association of aPKCι with cortactin-enriched
domains on MT1-MMP–containing intracellular compartments,
suggests that aPKCι phosphorylates cortactin on MT1-MMP–
containing late endosomes. The accumulation of hypophosphory-
lated cortactin in aPKCζ/ι-depleted cells or in the Ser261Ala
mutant inhibited association of dyn-2 with cortactin-positive
patches on MT1-MMP–containing endosomes, and it decreased
matrix degradation. Based on the known function of dyn-2 in
membrane scission on various compartments, including late
endosomes (39), impaired dyn-2 recruitment onto MT1-MMP–
positive late endosomes is probably responsible for the endo-
somal membrane tubulation we see, with adverse consequences
for MT1-MMP delivery to the surface. Thus, our data reveal
a role for aPKCζ/ι on late endocytic compartments and a pre-
viously unidentified mechanism of late endosome membrane
remodeling based on cortactin phosphorylation by aPKC to
control dyn-2 recruitment. Phosphorylation of S405 and S418
of cortactin by ERK1/2 also stimulates invadopodia formation
and matrix degradation. In addition, phosphorylation of cor-
tactin by ERK is involved in a recycling mechanism of in-
ternalized ECM components from late endosomes/lysosomes to
promote cell motility (32). However, our data indicate that ERK
phosphorylation sites do not contribute to dyn-2 recruitment to
cortactin-positive patches, thus suggesting different mechanisms
of action for aPKCζ/ι and ERK-dependent phosphorylation sites
for cortactin function during tumor-cell invasion.
Recent studies have documented an essential role for actin cy-
toskeleton dynamics in endosome function (30, 31, 40). The
mechanism emerging from these studies indicates that actin–Arp2/
3 assemblies organize early endosomal membranes into functional
subdomains and contribute to cargo sorting and generation of
transport intermediates. Our observation that dynamic cortactin–
Arp2/3–actin subdomains of MT1-MMP–containing multivesicular
Fig. 5. Phosphorylation of cortactin by aPKCι controls dyn-2 association
with cytoplasmic cortactin-positive puncta. (A) Purified GST-tagged human
cortactin (2 μg) was incubated in the presence (0.5 μg) or absence of
recombinant human aPKCι for 20 min at 37 °C. Cortactin phosphorylation
was analyzed by immunoblotting with antibodies against cortactin pSer298
phosphopeptide (anti-P298). (B) Lysates of MDA-MB-231 cells expressing
DsRed–cortactin alone or together with GFP–aPKCι were analyzed by im-
munoblotting with antibodies against pSer298 (anti-P298), total cortactin, or
GFP. (C) Quantification of dyn-2 on cortactin patches from confocal dual-
color spinning-disk images of MDA-MD-231 cells overexpressing GFP–dyn-2
together with DsRed-tagged wild-type cortactin or variants as indicated. The
ratios of the signal intensities from dyn-2 and cortactin were measured from
n endosome patches. ***P < 0.001; NS, not significant. (D) Whole-cell
extracts from breast tumors underexpressing (low) or overexpressing (high)
aPKCι mRNA were analyzed by immunoblotting with the indicated anti-
bodies. Tubulin was used as a control for equal loading.
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bodies coincide with sites of emergence and scission of tubulove-
sicular MT1-MMP carriers suggests a similar key role for actin in
generating transport intermediates from multivesicular bodies/late
endosomes. These mechanistic insights from cells in culture are
consistent with our analysis of breast-tumor samples showing up-
regulation of both aPKCι and MT1-MMP associated with hor-
mone receptor-negative aggressive breast tumors and with poor
prognosis; patients whose tumors overexpressed both aPKCι and
MT1-MMP had a significantly higher risk of metastasis. When
taken together with the known implication of cortactin in cancer
(41, 42) and the reported up-regulation of dyn-2 expression in
human metastatic tumors (43), our findings identify a key role for
aPKCι, cortactin, dyn-2, and MT1-MMP in aggressive epithelial
breast carcinomas and emphasize the role of polarity defects and
endosomal transport in breast carcinogenesis, opening new ave-
nues for innovative therapeutic strategies in aggressive forms of
breast cancers.
The redistribution of aPKCι and MT1-MMP from the apical
and lateral surfaces of epithelial cells, respectively, in normal
mammary ducts to cell–cell contacts and vesicles—probably
endosomes—in carcinoma cells correlates with the loss of epi-
thelial-cell polarity observed in breast tumors. This redistribution
seems particularly relevant in the context of tumor progression
(see also ref. 44). Apical–basal polarity requires the activity of
several proteins, including the apically located PAR complex,
which contains aPKCζ/ι as well as CDC42, Par3, and Par6 (18).
Moreover, components of the PAR complex regulate vesicle
transport in the endocytic pathway and play a critical role in the
uptake and recycling of components required for epithelial in-
tegrity (45, 46). Thus, our data suggest that a mechanism of
endocytic recycling of specific cargoes based on aPKCζ/ι/cor-
tactin/dyn-2 may operate in normal epithelial cells and may be
required for maintenance of apicobasolateral polarity. Like
aPKCι, Par6 is up-regulated in breast tumors (47) whereas loss of
Par3 promotes breast-cancer metastasis (48, 49). Collectively,
these data suggest that deregulation of PAR complex compo-
nents in breast carcinomas contributes to tumor progression via
deregulation of cell polarity and that one major consequence of
aPKCζ/ι overexpression and mislocalization in tumors is the
recycling and exocytosis of MT1-MMP, promoting metastasis of
carcinoma cells in most aggressive breast tumors.
Experimental Procedures
Antibodies and Plasmid Constructs. For antibodies and plasmid constructs, see
SI Experimental Procedures.
Cell Culture, Transfection, Stable Cell Lines, and Knockdown. For cell culture,
transfection, stable cell lines, and knockdown, see SI Experimental Procedures.
Fluorescent Gelatin Degradation Assay and Invasion Assays. Assays of fluo-
rescent gelatin degradation were performed and quantified as previously
described (15). About 250–300 cells from at least three independent
experiments were analyzed for each condition. Assays to measure cell in-
vasion into Matrigel and to measure the invasion of cells from multicellular
spheroids into native type I collagen assays were performed as described
previously (13, 50). The latter assays were quantified by estimating the di-
ameter of spheroids at T0 and T2 as described (50).
Indirect Immunofluorescence Microscopy, 3D Deconvolution, and Image
Analysis. MDA-MB-231 cells were cultured on gelatin-coated coverslips
and processed for immunofluorescence microscopy as previously described
(13). Image acquisition and analysis are described in SI Experimental
Procedures.
Live-Cell Imaging and Analysis of MT1-MMP–Containing Endosome Movement.
For live-cell imaging and analysis of MT1-MMP–containing endosome
movement, see SI Experimental Procedures.
Total Interference Reflection Fluorescence Microscopy. Cells expressing MT1-
MMP–mCherry and depleted of the proteins of interest (cortactin, aPKCζ/ι,
dyn-2) by means of siRNAs were plated on cross-linked gelatin-coated glass-
bottom dishes (MatTek) for 2 h before imaging. TIRFM imaging was per-
formed on a custom setup as described previously with a penetration depth
of 150–300 nm (51). MT1-MMP–mCherry at the cell surface was quantified
by using integrated intensity measurement in Metamorph software.
Structured Illumination Microscopy. For structured illumination microscopy,
see SI Experimental Procedures.
Electron Microscopy. For electron microscopy, see SI Experimental Procedures.
Human Samples and Clinical and Tissue Microarray Data.Our series of cases was
composed of 68 cases of invasive ductal carcinoma representative of each
molecular subtype of breast cancer: i.e., luminal A, luminal B, ER− PR− HER2+,
and ER− PR− HER2− (triple-negative). Clinicopathological parameters of
breast-cancer cases examined are described in Dataset S1. Breast molecular
subtypes were defined as follows: luminal A+B according to ref. 52 [luminal
A, estrogen receptor (ER) ≥ 10%, progesterone receptor (PR) ≥ 20%, Ki67 <
14%; luminal B, ER ≥ 10%, PR < 20%, Ki67 ≥ 14%]; ER− PR− HER2+, ER <
10%, PR < 10%, HER2 2+ amplified or 3+ according to ref. 53; ER− PR− HER2−
(triple-negative), ER < 10%, PR < 10%, HER2 0/1+ or 2+ nonamplified
according to American Society of Clinical Oncology (ASCO) guidelines (53).
MT1-MMP and aPKCι expression and association with clinicopathological
features of breast cancer were assessed by IHC analysis of a breast-cancer
tissue microarray (TMA) of invasive ductal carcinoma. TMA consisted of
replicate tumor cores (1-mm diameter) selected from whole-tumor tissue
section in the most representative tumor areas (high tumor-cell density) of
each tumor sample and a matched tissue core from adjacent nontumoral
breast epithelium (referred to as normal breast tissue). Immunohistocy-
tochemistry staining was performed according to previously published pro-
tocols (54).
Analyses were performed in accordance with the French Bioethics Law
2004–800 and the French National Institute of Cancer (INCa) Ethics Charter
and after approval by the Institut Curie review board and ethics committee
(Comité de Pilotage du Groupe Sein), which waived the need for written
informed consent from the participants. Women were informed of the re-
search use of their tissues and did not declare any opposition for such re-
search. Data were analyzed anonymously.
RNA Extraction and Real-Time PCR Analysis. For RNA extraction and real-time
PCR analysis, see SI Experimental Procedures.
Statistical Analyses. Relationships between mRNA levels of various target
genes and comparison of target-gene mRNA levels with clinical parameters
were estimated by using the χ2 test (for links between two qualitative
parameters) and the Spearman rank correlation test (for links between two
quantitative parameters). Differences between the two populations were
judged significant at confidence levels greater than 95% (P < 0.05). Metas-
tasis-free survival (MFS) was determined as the interval between diagnosis
and detection of the first metastasis. Survival distributions were estimated
by the Kaplan–Meier method, and the significance of differences between
survival rates was ascertained using a log-rank test. Relationships between
protein expression and distribution in tumors vs. normal adjacent tissues
were estimated using the Kruskal–Wallis test (for links between qualitative
and quantitative parameters). Other statistical analyses were performed
using the ANOVA or Student t test (link between one qualitative parameter
and one quantitative parameter) in Prism software.
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